Described herein are methods, devices, and compositions for providing personalized medicine tests for hematological neoplasms. In some embodiments, the methods comprise measuring the efficacy of inducing apoptosis selectively in malignant cells using any number of potential alternative combination drug treatments. In some embodiments, the ex vivo testing is measured using a recently extracted patient hematological samples. In other embodiments, the efficacy is measured ex vivo using an automated flow cytometry platform. For example, by using an automated flow cytometry platform, the evaluation of hundreds, or even thousands of drugs and compositions, can be made ex vivo. Thus, alternative polytherapy treatments can be explored. Non-cytotoxic drugs surprisingly induce apoptosis selectively in malignant cells ex vivo. In some embodiments, the methods described herein comprise evaluating non-cytotoxic drugs.本發明闡述用於針對血液腫瘤提供個人化藥物測試之方法、裝置及組合物。在一些實施例中，該等方法包含使用任何數量的潛在替代組合藥物治療法量測其選擇性誘導惡性細胞凋亡之功效。在一些實施例中，使用新近抽取之患者血液試樣來實施體外測試。在其他實施例中，使用自動化流式細胞儀平臺在體外量測功效。例如，藉由使用自動化流式細胞儀平臺，可在體外評估數百種或甚至數千種藥物及組合物。因此，可探討替代性多重療法治療。非細胞毒性藥物令人驚奇地在體外選擇性地誘導惡性細胞之凋亡。在一些實施例中，本文所述方法包括評估非細胞毒性藥物。
